Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Spinal Muscular Atrophy Treatment Market

Spinal Muscular Atrophy Treatment Market Share

Report ID: GMI11091
Published Date: Aug 2024
Report Format: PDF

Download Free Sample

Spinal Muscular Atrophy Treatment Market Share

The market is characterized by intense competition among key players aiming to expand their market presence. Leading companies are focusing on strategic initiatives such as mergers, acquisitions, and partnerships to strengthen their market position. These efforts aim to enhance their product and service offerings, expand their geographic reach, and invest in advanced technologies. The market also witnesses the entry of new players, further intensifying the competitive landscape.

Spinal Muscular Atrophy Treatment Market Companies

The company profile section includes both companies that have commercial drug available in the market as well as those that are onto clinical phase development. Prominent players operating in the market are as mentioned below:

American Physical Therapy Association
Astellas Pharma
Beijing Jinlan Gene Technology Co., Ltd.
Biogen Inc.
Boston's Children Hospital
Children's Hospital of The King's Daughters
F. Hoffmann-La Roche Ltd.
Hanugen Therapeutics
Nationwide Children’s Hospital
NMD Pharma A/S
Novartis AG
Pfizer, Inc.
Sanofi (Genzyme Corporation)
Scholar Rock, Inc

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global spinal muscular atrophy treatment industry was valued at USD 7.3 billion in 2023 and is anticipated to register 19.1% CAGR between 2024 and 2032 due to the increase in diagnosis rate of spinal muscular atrophy in infants and children.

The medication segment in the market held 64.2% revenue share in 2023 due to innovative drugs like Spinraza and Evrysdi targeting SMA’s genetic cause for offering flexible formulation flexible administration options.

North America spinal muscular atrophy treatment market held 45.6% revenue share in 2023 due to supportive rare disease policies, advanced healthcare facilities, and ongoing clinical trials.

American Physical Therapy Association, Astellas Pharma, Beijing Jinlan Gene Technology Co., Ltd., Biogen Inc., Boston's Children Hospital, and Children's Hospital of The King's Daughters, among others.